Vertex Pharmaceuticals Incorporated

179 articles about Vertex Pharmaceuticals Incorporated

• Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer

  10/1/2019

  Vertex Pharmaceuticals Incorporated announced that Carmen Bozic, M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs.

• Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

  9/30/2019

  Vertex Pharmaceuticals Incorporated and RNA therapeutics developer Ribometrix, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases.

• Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

  9/12/2019

  Eligible patients in Scotland will immediately have access to ORKAMBI and SYMKEVI in combination with ivacaftor

• Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11

  9/10/2019

  Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET.

• Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

  9/3/2019

  Vertex Pharmaceuticals Incorporated announced that the company has entered into a definitive agreement under which Vertex will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.

• Vertex Reports Second-Quarter 2019 Financial Results

  7/31/2019

  Vertex Pharmaceuticals Incorporated reported consolidated financial results for the second quarter ended June 30, 2019 and increased its full-year 2019 total product revenue guidance.

• Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer

  7/25/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D, into the role of Executive Chairman of the Board, effective April 1, 2020.

• Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis

  7/22/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen

• Vertex to Announce Second-Quarter 2019 Financial Results on July 31

  7/17/2019

  The company will host a conference call and webcast at 4:30 p.m. ET.

• FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

  6/21/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years who have two copies of the F508del-CFTR mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to SYMDEKO

• FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age

  4/30/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO®

• CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

  3/6/2019

  -Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation (F/MF) compared to placebo (p<0.0001)-

• Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

  3/6/2019

  Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo

• CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

  2/25/2019

  CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies.

• Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results

  2/5/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2018 and provided full-year 2019 financial guidance.

• Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to 24 months with Certain Mutations in the CFTR Gene

  1/28/2019

  KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients

• Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

  1/24/2019

  Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas

• Vertex Announces Departure of Ian Smith, Names Interim CFO

  1/23/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately.

• Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5

  1/22/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close.

• X-Chem and Vertex Expand Existing Partnership

  1/4/2019

  X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation of novel small molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated